Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Leflunomide has been investigated in several clinical trials as an anti-cancer therapy, including metastatic triple negative cancers (NCT03709446), add-on therapy to mitoxantrone in stage IV prostate cancer (NCT00004071), add on to vemurafenib in metastatic melanoma (NCT01611675), as treatment for multiple melanoma (NCT02509052), anaplastic astrocytoma (NCT00003775), and glioblastoma multiforme (NCT00003293)
Environ Health Perspect 50, 11322
Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria
Allergy 62 (11), 13411342
However, consult with a healthcare professional for personalized advice
US$ 20.26
US$ 26.08
US$ 27.48
US$ 21.64
US$ 24.33
US$ 23.30
